| Dr Victoria Woods Anderson, MD | |
|
770 Walnut St, Macon, GA 31201-7307 | |
| (478) 787-4266 | |
| (478) 787-4199 |
| Full Name | Dr Victoria Woods Anderson |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 38 Years |
| Location | 770 Walnut St, Macon, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427042290 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 00014888 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Macon, GA | Home health agency |
| Medical Center, Navicent Health (the) | Macon, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Choice Primary Care, Inc. | 6103907316 | 9 |
News Archive
Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.
Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina - a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.
Roll Call reports that Senate Finance Committee Chairman Max Baucus said today that he could receive on Wednesday the final Congressional Budget Office cost estimate of the latest version of his panel's health reform bill.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
› Verified 2 days ago
| Entity Name | First Choice Primary Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336332857 PECOS PAC ID: 6103907316 Enrollment ID: O20101006000825 |
News Archive
Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.
Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina - a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.
Roll Call reports that Senate Finance Committee Chairman Max Baucus said today that he could receive on Wednesday the final Congressional Budget Office cost estimate of the latest version of his panel's health reform bill.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Victoria Woods Anderson, MD Po Box 4363, Macon, GA 31208-4363 Ph: (478) 787-4266 | Dr Victoria Woods Anderson, MD 770 Walnut St, Macon, GA 31201-7307 Ph: (478) 787-4266 |
News Archive
Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.
Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina - a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.
Roll Call reports that Senate Finance Committee Chairman Max Baucus said today that he could receive on Wednesday the final Congressional Budget Office cost estimate of the latest version of his panel's health reform bill.
We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.
› Verified 2 days ago
Dr. Shuichi Nakai, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3780 Eisenhower Pkwy, Macon, GA 31206 Phone: 478-633-5550 Fax: 478-633-7287 | |
Sam G Amporful, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 721 Riverside Drive Lane, Macon, GA 31201 Phone: 478-259-3439 Fax: 478-254-2733 | |
Mrs. Stephanie Faye Bennett, Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Gateway Drive, Macon, GA 31210 Phone: 478-210-1670 | |
Dr. Robert C Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Riverside Dr Ste B300, Macon, GA 31210 Phone: 478-405-5252 Fax: 478-477-8411 | |
Alice Rose House, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1550 College St, Suite A, Macon, GA 31207 Phone: 478-301-4111 Fax: 478-301-5812 | |
Dione Duc, Family Medicine Medicare: Medicare Enrolled Practice Location: 777 Hemlock St # 104, Macon, GA 31201 Phone: 478-633-7550 Fax: 478-633-3235 | |
Collier Branan Gladin Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 140 N Crest Blvd, Macon, GA 31210 Phone: 478-757-8335 Fax: 478-757-8353 |